Our Science
Antibody Delivery
Small Molecule Delivery and siRNA Delivery
Protein Delivery and Peptide Delivery
Limited Systemic Clearance and Limited Systemic Toxicity
Delivering medicine to specific tissues—and ensuring it stays there—is a significant challenge due to natural barriers and clearance mechanisms. These obstacles hinder effective drug delivery and retention, such as mucociliary clearance in the lungs, rapid transit and enzymatic breakdown in the GI tract, and the blood-brain barrier in the CNS.
Delivering medicine to specific tissues—and ensuring it stays there—is a significant challenge due to natural barriers and clearance mechanisms. These obstacles hinder effective drug delivery and retention, such as mucociliary clearance in the lungs, rapid transit and enzymatic breakdown in the GI tract, and the blood-brain barrier in the CNS.
Our delivery technologies – paints – are based on tissue endogenous surfactant peptides. Our Paints include PulmoPaint™ for delivery to the lungs, CerebroPaint™ for the brain and CNS, and GastroPaint™ for the GI tract. Paint precisely delivers medicines to distinct tissues for controlled release at the site of disease.
Our delivery technologies – paints – are based on tissue endogenous surfactant peptides. Our Paints include PulmoPaint™ for delivery to the lungs, CerebroPaint™ for the brain and CNS, and GastroPaint™ for the GI tract. Paint precisely delivers medicines to distinct tissues for controlled release at the site of disease.
Our paints enable long-acting and controlled release at the site of disease. In combination with warheads with potent biological activity, we have identified drug candidates across disease indications. We continue to advance these candidates to provide long-lasting efficacy in the lung, the brain and CNS, and GI tract.
Undisclosed
GastroPaint™
Undisclosed
CerebroPaint™
Oncology
PulmoPaint™
A1AT
PulmoPaint™
Indication
Discovery
Pre-clinical
IND-Enabling
Status
Undisclosed
GastroPaint™
Undisclosed
CerebroPaint™
PulmoPaint™
A1AT
Oncology
Indication
Discovery
Pre-clinical
IND-Enabling
Status
Our paints enable long-acting and controlled release at the site of disease. In combination with warheads with potent biological activity, we have identified drug candidates across disease indications. We continue to advance these candidates to provide long-lasting efficacy in the lung, the brain and CNS, and GI tract.
Pipeline
